This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bear Of The Day: Rite Aid (RAD)
by Daniel Laboe
Rite Aid (RAD) has had a devastating past 3 year, having lost 95% of its total market value in that time frame. RAD is currently the most shorted stock in America today, with 390% of free-floating shares being held short.
Walgreens Boots Alliance (WBA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $53.96, moving +0.32% from the previous trading session.
Walgreens (WBA) Down 2.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Walgreens (WBA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
2 Top-Notch Tech Bigwigs to Buy Ahead of Earnings
by Tirthankar Chakraborty
Microsoft and Amazon are well poised to for this earnings season on growing cloud infrastructure.
Rite Aid (RAD) Falls Despite Narrower-Than-Expected Q4 Loss
by Zacks Equity Research
Rite Aid (RAD) posts narrower-than-expected loss in fourth-quarter fiscal 2019. Moreover, it issues a soft outlook for fiscal 2020.
Rite Aid (RAD) Picks 1-for-20 Reverse Stock Split Ratio
by Zacks Equity Research
Rite Aid (RAD) approves a 1-for-20 reverse stock split to regain compliance for NYSE listing rules. This will reduce the company's outstanding shares to 54 million.
Walgreens Partners With VillageMD to Offer Primary Healthcare
by Zacks Equity Research
This joint venture marks Walgreens' (WBA) commitment toward enabling access to affordable healthcare and creating neighborhood health destinations.
Walgreens' Weak Market Trends a Woe, Strategic Deals to Aid
by Zacks Equity Research
Walgreens Boots (WBA) currently endeavors to redress certain areas of operational weakness and reinforces its managerial competence to drive operating efficiency with a resolute focus.
Dow 30 Stock Roundup: WBA Q2 Earnings Disappoint, PFE Lung Cancer Drug Gets EU Approval
by Swarup Gupta
The index notched up another week of gains riding on optimism over the increasing likelihood of a U.S.-China trade deal.
Previewing Bank Earnings
by Sheraz Mian
JPMorgan (JPM) and Wells Fargo (WFC) kick-off the Q1 earnings season for the group on Friday, April 12th, with a host of industry players following suit the following week. The question is whether these quarterly results can serve as a catalyst for bank stocks?
Amazon (AMZN) Stock Looks Like a Buy Heading into Q1 2019 Earnings
by Benjamin Rains
Shares of Amazon (AMZN) have outpaced the market in 2019, up 21% against the S&P's 15% jump. Despite the strong start, Amazon stock rests over 11% below its 52-week high. So, let's take a look at why Amazon appears to be a buy right now heading into its Q1 2019 earnings release .
The Zacks Analyst Blog Highlights: Walgreens, Amazon and CVS
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walgreens, Amazon and CVS
Marijuana Banking, IPOs & Weed Votes: Will Hemp Grow Higher? (Revised)
by Nitish Marwah
Experts are of the view that the marijuana industry would generate as much as $5 billion in annual revenues over the next two years.
Implied Volatility Surging for Walgreens Boots (WBA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Walgreens Boots (WBA) stock based on the movements in the options market lately.
Stock Market News For Apr 3, 2019
by Zacks Equity Research
Wall Street closed mixed on Tuesday as investors digest weak earnings result and not so impressive economic data.
What to Expect from CVS' Q1 Earnings After Walgreens Stock Tanks
by Benjamin Rains
CVS Health (CVS) stock has been down in the dumps for years and shares have already fallen 20% in 2019 even as the broader market booms. Now, after Walgreens Boots Alliance's (WBA) massive one-day, post-earnings selloff Tuesday, it's time to see what investors should expect from CVS.
Walgreens Has Biggest One-Day Loss in 5 year: What Does This Mean For Pharmacies?
by Daniel Laboe
Walgreens Boots Alliance (WBA) dropped over 12% today taking the price down to a low of $55, the lowest the stock has traded at since 2014. WBA???s tumble was initiated by worse than expected earnings, and a full year EPS guidance adjustment which would make them flat for 2019.
Durable Goods Mixed, Walgreen's (WBA) Disappoints
by Mark Vickery
While the preliminary view on February Durable Goods Orders were better than expected, Walgreen's fiscal Q2 came in far worse.
Walgreens Boots (WBA) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
A difficult macroeconomic environment and market challenges made the fiscal second quarter the toughest since the formation of Walgreens Boots Alliance (WBA).
Walgreens' Earnings & Economic Data In Focus
by Zacks Equity Research
Walgreens' Earnings & Economic Data In Focus
Durable Goods Mixed, Walgreen's (WBA) Disappoints
by Mark Vickery
While the preliminary view on February Durable Goods Orders were better than expected, Walgreen's fiscal Q2 came in far worse.
Walgreens Boots Alliance (WBA) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Walgreens (WBA) delivered earnings and revenue surprises of -3.53% and -0.89%, respectively, for the quarter ended February 2019. Do the numbers hold clues to what lies ahead for the stock?
Marijuana Banking, IPOs & Weed Votes: Will Hemp Grow Higher?
by Nitish Marwah
Experts are of the view that the marijuana industry would generate as much as $5 billion in annual revenues over the next two years.
The Zacks Analyst Blog Highlights: Phillip Morris, Bristol-Myers, Walgreens, Sirius and Total System
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Phillip Morris, Bristol-Myers, Walgreens, Sirius and Total System
Top Research Reports for Phillip Morris, Bristol-Myers & Walgreens Boots
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Phillip Morris (PM), Bristol-Myers (BMY) and Walgreens Boots (WBA).